Older systemic drugs aren’t just relics—they’re critical tools for dermatologists tackling tough diseases like lichen planus, granuloma annulare, psoriasis, atopic dermatitis, and alopecia areata, especially when FDA-approved options fall short or are inaccessible. Join Derms on Drugs and guest expert Dr. Scott Drew as we share practical pearls for using methotrexate, mycophenolate, cyclosporine, dapsone, roflumilast, and more.
In this episode, you’ll learn:
--When and why to reach for these time-tested therapies in real-world practice
--How to monitor labs and counsel patients for safety and success
--Tips for discussing off-label treatments and navigating complex cases
Perfect for dermatology providers who want up-to-date, actionable advice on systemic therapy selection, risk monitoring, and patient communication. Whether you’re managing recalcitrant inflammatory disorders or optimizing care for common skin diseases, these “oldies but goodies” might be your next best move.
Tune in for clinical pearls and expert insights you can put to work in your practice!
Article titles:
1.  Pulse azathioprine and low-dose methotrexate vs. standard-dose methotrexate in treatment of patients with moderate-to-severe psoriasis: a randomized controlled trial
2.  Lower Oncogenic Risk with Dermatologic Use of Mycophenolate Mofetil Compared to Transplant Prophylaxis: A Retrospective Study
3.  Drug Survival of Dupilumab, Methotrexate, and Cyclosporine A in Children With Atopic Dermatitis